Clinical Trial Update: A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib [Phase 2]

View source ↗

Summary

Phase 2 molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer treated with osimertinib has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19